Modulation of bone formation
OwnerScutt Andrew, Still Kareninventors
Life of this patent
Estimating the term…
Abstract
The use of an activator or ligand of a peroxisome proliferator-activated receptor, other than PPARγ, or pharmaceutically acceptable derivative of said activator or ligand, in the manufacture of a medicament for the treatment or prophylaxis of bone disease allows, for the first time, bone anabolism to enhance the deposition of bone in conditions which would benefit from increased bone deposition. The reverse, where there is inhibition and/or retardation of bone deposition is also facilitated.
Claims16
Use of a compound which is an activator or ligand of a peroxisome proliferator-activated receptor other than PPARγ, or pharmaceutically acceptable derivative of said activator or ligand, in the manufacture of a medicament for the treatment or prophylaxis of bone disease.
Use according to any preceding claim wherein the substance has equal or greater bone anabolic activity than PGE2.
Use of a derivative according to any preceding claim, which is a pro-drug, salt or ester.
Use according to any preceding claim, wherein the bone disease is:
- osteoporosis;
- Paget's disease;
- osteogenesis imperfecta;
- hypophosphatasia;
- hyperparathyroidism;
- deafness;
- orthodontic abnormalities;
- or cancers which result in hypercalcaemia, especially myeloma.
A method for the screening of agents which modulate the activity of PPAR transcription factors comprising:
- i providing a culture of bone forming cells;
- ii exposing the bone forming cells to an agent capable of modulating the activity of at least one PPAR transcription factor;
- and
- iii monitoring the effect of the agent on the bone forming capacity of the cell culture.
Dependencies are inferred from the claim text.